Solutions for T cell engager (TCE) programs

T cell engagers (TCEs) are bispecific antibodies designed to redirect cytotoxic T cells to pathogenic cells by simultaneously binding CD3 on T cells and disease-associated antigens on target cells.

Key limitations of T cell engager therapies include an incomplete understanding of primary resistance to treatment, which is influenced by the baseline composition of the T cell compartment and acquired resistance that is driven by T cell exhaustion.

In addition to supporting the assessment of safety and efficacy, CellCarta can also help you unravel the mechanisms at play behind primary and acquired resistance to TCE therapies. 

Link to brochure